- Generic name
- Sacubitril + Valsartan
- Strength
- 49 mg + 51 mg
- Dosage form
- Tablet
- Manufactured by
- Opsonin Pharma Limited
Arnivas 100 Tablet
About Arnivas 100 49 mg + 51 mg Tablet
The tablet Arnivas 100 contains Sacubitril + Valsartan and is made by Opsonin Pharma Limited. Arnivas 100 is used to lower the risk of death from heart problems and hospitalization in adults with long-term heart failure and a reduced pumping action of the heart.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is Arnivas 100 49 mg + 51 mg Tablet?
Made by Opsonin Pharma Limited, Arnivas 100 is a tablet whose active ingredient is Sacubitril + Valsartan. Together, they help reduce the risk of death and hospitalization from heart failure in adults with reduced ejection fraction, and treat symptoms in children aged one year and older. Regular monitoring of blood pressure, kidney function, and potassium is needed during treatment. Whether it suits you is a decision for your doctor.
Uses of Arnivas 100
Arnivas 100 is used to lower the risk of death from heart problems and hospitalization in adults with long-term heart failure and a reduced pumping action of the heart. Arnivas 100 is used to treat chronic heart failure in adults when the heart does not pump well (reduced ejection fraction). It is a prescription medicine, and the doctor will confirm whether it is appropriate for the patient's condition. The doctor decides whether it is suitable, based on the patient's condition and other medicines being taken.
How to use Arnivas 100
Arnivas 100 is taken by mouth as a tablet. Swallow the tablet with water. Tell your doctor about all other medicines you take, including ACE inhibitors, ARBs, aliskiren, potassium-sparing diuretics, NSAIDs and lithium, because interactions can occur. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Arnivas 100
Do not ignore severe symptoms. Your doctor may adjust the dose or recommend tests to monitor your condition. Some people may experience these effects. Tell your doctor promptly if you notice swelling, difficulty breathing, or a big drop in blood pressure. Tell your doctor if you feel very dizzy or faint, or pass much less urine than usual.
Safety and precautions
Do not take Arnivas 100 if you are allergic to any of its ingredients, if you have had angioedema after taking an ACE inhibitor or ARB, or if you have hereditary angioedema. Arnivas 100 must not be used by anyone with a history of angioedema related to an ACE inhibitor or ARB, or with hereditary angioedema. Pregnancy and breastfeeding: ask the doctor before use. Tell your doctor if you have kidney or liver problems, low blood pressure, or high potassium.
Frequently asked questions
Why is Arnivas 100 prescribed?
Arnivas 100 is used to lower the risk of death from heart problems and hospitalization in adults with long-term heart failure and a reduced pumping action of the heart. Arnivas 100 is used to treat chronic heart failure in adults when the heart does not pump well (reduced ejection fraction).
How is Arnivas 100 used?
Arnivas 100 is taken by mouth as a tablet. Swallow the tablet with water.
Can Arnivas 100 cause side effects?
Do not ignore severe symptoms. Your doctor may adjust the dose or recommend tests to monitor your condition.
Is Arnivas 100 safe for everyone?
Do not take Arnivas 100 if you are allergic to any of its ingredients, if you have had angioedema after taking an ACE inhibitor or ARB, or if you have hereditary angioedema. Arnivas 100 must not be used by anyone with a history of angioedema related to an ACE inhibitor or ARB, or with hereditary angioedema.
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ... Read more
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
Dosage & Administration
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Recommended Dose Titration-
Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
Pregnancy & Lactation
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Storage Conditions
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.